Dual-target GD2/B7-H3 CAR-NK Pediatric Neuroblastoma Trial

This is a new clinical trial registration on ClinicalTrials.gov (NCT07502287) for a dual-target GD2/B7-H3 CAR-NK cell therapy study in pediatric neuroblastoma patients. The trial is sponsored by Beijing Biotech and registered by the National Library of Medicine. CAR-NK cells target both GD2 (disialoganglioside) and B7-H3 (CD276) antigens, which are expressed on neuroblastoma cells.

Clinical investigators and sponsors should ensure their trials are properly registered on ClinicalTrials.gov within 21 days of enrollment of the first participant, or before recruitment begins. Trial sponsors and institutional review boards may use this registration to verify trial status and protocol details. The registration includes standard elements required by FDA Amendment Act (FDAAA) Section 801.